Allele-specific inhibitors of KRAS(G12C) are approved in non-small-cell lung cancer. Herein, we discuss recent results from the phase I/II KRYSTAL-1 trial of adagrasib alone and in combination with cetuximab in patients with KRAS(G12C)-mutant metastatic colorectal cancer. The combination had promising efficacy and, if confirmed in later-phase trials, concomitant inhibition of EGFR and KRAS(G12C) will present a new paradigm in precision oncology.
Precision oncology for KRASG12C-mutant colorectal cancer
Di Nicolantonio, Federica
First
;Bardelli, Alberto
Last
2023-01-01
Abstract
Allele-specific inhibitors of KRAS(G12C) are approved in non-small-cell lung cancer. Herein, we discuss recent results from the phase I/II KRYSTAL-1 trial of adagrasib alone and in combination with cetuximab in patients with KRAS(G12C)-mutant metastatic colorectal cancer. The combination had promising efficacy and, if confirmed in later-phase trials, concomitant inhibition of EGFR and KRAS(G12C) will present a new paradigm in precision oncology.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2023-Precision oncology_post print.pdf
Open Access dal 14/09/2023
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
102.25 kB
Formato
Adobe PDF
|
102.25 kB | Adobe PDF | Visualizza/Apri |
|
2023-Precision oncology.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
1.08 MB
Formato
Adobe PDF
|
1.08 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
